Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.

Completed

Looking for future studies?

Key information

Conditions

Open-angle Glaucoma Cardiovascular Diseases Eye Diseases Glaucoma Glaucoma, Open-Angle Hypertension Ocular Hypertension Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Clinical Trial Sites

Multiple Locations Throughout the United States, Texas, 76134, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; visual acuity of 20/80 to 20/400 or better (Snellen equivalent) or logMAR visual acuity not worse than 0.6. Clinically relevant ophthalmic or systemic conditions may be excluded.

Treatment and study plan

Alcon Investigational Agent

Drug

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Official study title

Phase III Safety and Efficacy Study to Evaluate Combination IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertensive Patients C-01-69.

Important dates

Study start: 2001
Primary completion: 2003
Study completion: 2003
First posted: Oct 18, 2002
Registry last updated: Aug 5, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed